Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Abstract

Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.).

Keywords

Microsatellite instabilityPembrolizumabColorectal cancerMedicineCancerMicrosatelliteOncologyCancer researchInternal medicineBiologyGeneticsImmunotherapy

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon , Naiyer A. Rizvi , Rina Hui +24 more

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

2015 New England Journal of Medicine 6054 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 23
Pages: 2207-2218
Citations: 2637
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2637

OpenAlex

Cite This

APA Style

                            
                                
                                    Thierry André, 
                                
                                    Kai‐Keen Shiu, 
                                
                                    Tae Won Kim
                                
                                et al.
                            
                            (2020). 
                            Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. 
                            New England Journal of Medicine
                            , 383
                            (23)
                            , 2207-2218.
                            https://doi.org/10.1056/nejmoa2017699
                        

Identifiers

DOI: 10.1056/nejmoa2017699